Telomerase activity is closely correlated with cellular proliferative activity in human tissues. Human cells with high proliferative potential, such as tumor cells or stem cells, exhibit telomerase activity, whereas most normal human somatic cells do not. Telomerase activity is tightly regulated by the expression of its catalytic subunit human telomerase reverse transcriptase (hTERT). Through an expression cloning approach, we identified E2F-1 as a repressor of the hTERT gene in human tumor cells. Ectopic expression of E2F-1 repressed hTERT promoter activity by inhibiting Sp1 activation of the hTERT promoter. In contrast to the repressor function of E2F-1 in human tumor cells, we demonstrated that E2F-1 is an activator of the hTERT gene in normal human somatic cells. Ectopically expressed E2F-1 activated the hTERT promoter through a noncanonical DNA binding site. E2F-1, E2F-2, and E2F-3 (but not E2F-4 and E2F-5) repressed hTERT promoter activity in human tumor cells, whereas they activated it in normal somatic cells. These contrasting effects of E2F transcription factors on the hTERT promoter could underlie the paradoxical biological activities of E2F, which can both promote and inhibit cellular proliferation and tumorigenesis.
T elomeres are specialized functional nucleoprotein complexes that cap the ends of the eukaryotic chromosomes and play essential roles in the maintenance of chromosomal integrity (1) (2) (3) . Mammalian telomeric DNA consists of TTAGGG repeats that are synthesized by a specialized reverse transcriptase complex, telomerase (4) . Human telomerase is composed of an RNA component (hTR) that provides the template for the addition of new telomeric repeats, a catalytic subunit known as human telomerase reverse transcriptase (hTERT), and some additional associated proteins (5) (6) (7) . In human tissues, telomerase activity is tightly regulated by the expression of the hTERT gene.
Most human somatic tissues and primary cells have no telomerase activity. As a result, such cells experience a steady decline in telomere length during the course of organ renewal in vivo or during passage in culture (8, 9) . Cells with high proliferative potential, however, possess telomerase activity, which is required for proliferation and long-term viability. For example, relatively high telomerase activity is expressed in the proliferative basal layer of skin (10) . Mitotically active regions of hair follicles and the proliferative zone of intestinal crypts also have telomerase activity (11, 12) . Furthermore, telomerase activity can be growth regulated in human tissues in vivo. For example, mitotic stimulation of lymphocytes causes up-regulation of telomerase activity (13) . In endometrial tissue, telomerase expression is tightly correlated with proliferation during the menstrual cycle (14) . Despite this close relationship between cellular proliferation and telomerase activity, the molecular mechanism that links proliferation with telomerase activity remains elusive.
Many proteins participate in the coordinated regulation of the cell cycle and cellular proliferation. Among them, the E2F family of transcription factors plays central roles by regulating the expression of genes involved in DNA replication and cell proliferation. There are six members of the E2F family, named E2F-1 through E2F-6. These proteins can be divided into three groups (E2F-1, E2F-2, and E2F-3; E2F-4 and E2F-5; E2F-6) on the basis of structural and functional properties. E2F-1, E2F-2, and E2F-3 share a conserved N-terminal cyclin A-cdk2 binding domain, which is absent in other members of the E2F family. These three E2Fs are regulated by pRB, whereas E2F-4 and E2F-5 are regulated mainly by p107 and p130 (15) . E2F-1, E2F-2, and E2F-3 can bind Sp1, whereas neither E2F-4 nor E2F-5 binds to Sp1 (16) . E2F-6 is quite different from the rest of the family, because it contains no transcriptional activation domain and appears to act exclusively as a transcriptional repressor (17) .
Researchers in several laboratories, including ours, previously isolated the promoter region that supports expression of the hTERT gene in human tumor cells (18) . In normal human cells, tight gene regulation, especially repression of the hTERT gene, is critical to silence the telomerase activity or to maintain a specific level of growth-regulated telomerase activity. Previously, we successfully developed and employed expression cloning as an approach for identification of the transcriptional repressor of the hTERT gene (19, 20) . Using this approach, we identified WT1 and Mad as factors that are able to repress hTERT promoter activity in tumor cells (19, 20) .
In the present study, we identified E2F-1 as a repressor that down-regulates hTERT promoter activity in human tumor cells. Interestingly, in contrast to its repressive activity in human tumor cells, E2F-1 activated the hTERT promoter in normal human somatic cells. The other two members of the E2F-1 subfamily (E2F-2 and E2F-3) also regulated the hTERT promoter as a repressor and an activator in human tumor and normal cells, respectively. These contrasting activities of E2F are manifested through different DNA elements within the hTERT promoter. On the basis of these regulatory properties of E2F on the hTERT promoter, we propose that cellular regulation of E2F may contribute to the tight regulation of hTERT expression in various cell types.
MATERIALS AND METHODS

Cell culture, transfection, and luciferase assay
The cell lines 293 (adenovirus 5 transformed kidney cell line; CRL 1573), HeLa (cervical adenocarcinoma cell line; CCL 2), HepG2 (hepatocellular carcinoma cell line; HB 8065), U2OS (osteosarcoma cell line; HTB 96), Saos-2 (osteosarcoma cell line; HTB 85), IMR90 (human normal lung fibroblast; CCL 186), and WI38 (human normal lung fibroblast; CCL 75) were obtained from the American Type Culture Collection (Manassas, VA). The cell line 293T (a subline of 293 that expresses the SV40 large T antigen) was kindly provided by Dr. S. Oh (Seoul National University, Korea). HFF (human normal foreskin fibroblast) was kindly provided by Dr. H. Lee (Harvard Medical School, Cambridge, MA). All of the above cells except Saos-2 were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 120 µg/ml penicillin G, and 200 µg/ml streptomycin. Saos-2 cells were maintained under identical conditions except with 15% FBS. Transient transfection was carried out with LipofectAMINE reagent (Life Technologies, Grand Island, NY) according to the manufacturer's protocol. Luciferase assays were performed 36-48 h after transfection with the reagents from Promega (Madison, WI), according to the manufacturer's instructions.
Expression cloning analysis
Preparation of the cDNA expression library was described previously (19, 20) . The cDNA expression library was divided into pools of about 100 cDNAs per pool. Pools of plasmids were grown overnight in LB medium, and plasmid DNA was purified (QIAGEN, Hilden, Germany). Pools were cotransfected with the firefly luciferase reporter plasmid containing the 3396-bp 5'-regulatory promoter region of the hTERT gene (18) into 293T cells, and luciferase assays were performed 48 h after transfection. The DNA from the positive pools was transformed into Escherichia coli DH5α cells to generate fractionated subpools for further transfections.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from U2OS cells essentially as previously described (21) . Portions of nuclear extract (5 µg) were incubated with 0.5 µg of poly(dI·dC) in the absence or presence of specific antibodies at room temperature for 20 min in a 15-µl reaction volume containing 10 mM Tris-HCl (pH 7.5), 4 mM HEPES (pH 7.9), 50 mM NaCl, 20 mM KCl, 1 mM MgCl 2 , 0.54 mM EDTA, 0.6 mM dithiothreitol, and 8% glycerol. Antibodies used for the supershift assay were anti-Sp1 (polyclonal; sc-59, Santa Cruz Biotechnology, Santa Cruz, CA) and anti-Sp3 (polyclonal; 07-107, Upstate Biotechnology, Lake Placid, NY). After incubation, a 32 P end-labeled double-stranded oligonucleotide probe (upper strand sequence: 5'-CCTTCCAGCTCCGCCTCCTCCGCGCGGA-3') was added, and incubation proceeded at room temperature for an additional 20 min. These reaction mixtures were subjected to electrophoresis in a 6% polyacrylamide gel in 0.25× Tris-borate-ethylenediaminetetraacetic acid buffer, dried, and subjected to autoradiography.
Formaldehyde cross-linked chromatin immunoprecipitation (X-ChIP) assay
X-ChIP assays were performed using the ChIP assay kit (Upstate Biotechnology) according to the manufacturer's instructions. Cells were fixed in a normal culture medium with formaldehyde at a final concentration of 1% for 10 min at 37°C. Sonication was performed to achieve an average DNA length of 500 bp. The following antibodies were used for the immunoprecipitation of the cross-linked chromatin: anti-Sp1 (polyclonal; sc-59, Santa Cruz Biotechnology), anti-Sp3 (polyclonal; 07-107, Upstate Biotechnology), and anti-HA (polyclonal; 71-5500, Zymed, South San Francisco, CA). The primers used to amplify an approximately 160-bp fragment in the hTERT proximal promoter were 5'-TGCCCCTTCACCTTCCAG-3' and 5'-CAGCGCTGCCTGAAACTC-3'. Polymerase chain reaction (PCR) was carried out as follows: 1 cycle at 94°C for 3 min; 34 cycles at 94°C for 30 s, at 53°C for 30 s, and at 72°C for 20 s; and 1 cycle at 72°C for 1 min. The amplified DNA was separated on 2% agarose gel and stained with ethidium bromide.
Western blotting
Proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Millipore, Bedford, MA). The membrane was blocked with 5% nonfat milk and processed with probes anti-Sp1 (polyclonal; sc-59, Santa Cruz Biotechnology), anti-E2F-1 (monoclonal; E51120, BD Transduction Laboratories, San Diego, CA), and anti-actin (polyclonal; sc-7210, Santa Cruz Biotechnology). The membrane was then incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (sc-2054, Santa Cruz Biotechnology), HRP-conjugated anti-mouse IgG (sc-2055, Santa Cruz Biotechnology), and HRP-conjugated anti-goat IgG (sc-2056, Santa Cruz Biotechnology), and the enhanced chemiluminescence (ECL) system (Amersham Biosciences, Piscataway, NJ) was used for visualization.
Plasmids
The construction of p3396 and p1003 was described previously (18, 20) . A series of unidirectional 5'-deletions of the 3396-bp 5'-regulatory promoter region of the hTERT gene was generated from p3396 by using the Erase-a-Base system (Promega). For the construction of p188--24, the DNA insert was obtained by PCR, and the resultant product was cloned into the luciferase reporter plasmid pGL3-Basic (Promega). To obtain p188--51 and p188--89, p188 was digested with EcoRIII/BglII and SacII/BglII, respectively, and then blunt-ended with Klenow, and religated. To obtain p188-Sp-m1,2,3,4,5, p188-E2F-m, and p1003-E2F-m, site-directed mutagenesis was performed as described previously (20) . Cytomegalovirus (CMV)-E2F-1, CMV-E2F-2, CMV-E2F-3, CMV-E2F-4, and CMV-E2F-5 were kindly provided by D. Ginsberg (22) . CMV-E2F-1∆1-88 and CMV-E2F-1Y411C were generous gifts from J. R. Nevins (23) . CMV-Sp1 was kindly provided by M. W. Hur (24) .
RESULTS
E2F-1 was identified as a repressor of the hTERT promoter in human tumor cells
For efficient identification of the transcriptional repressor of the hTERT gene, we developed an expression cloning approach (19, 20) . We prepared a cDNA expression library from the mRNA isolated from normal human kidney tissue, in which hTERT gene expression is undetectable and presumably repressed. The library was divided into pools of about 100 cDNAs each and cotransfected into 293T cells along with the firefly luciferase reporter plasmid containing the 3396-bp hTERT promoter. As a control for variations in transfection efficiency, a plasmid encoding the Renilla luciferase gene under the control of the CMV promoter was also cotransfected.
Among 1200 pools (approximately 120,000 total cDNAs) screened, several pools including numbers 376, 727, and 1012 significantly reduced the normalized ratio of firefly to Renilla luciferase activity. Previously, fractionation of two pools (numbers 376 and 727) led to the identification of WT1 and Mad as repressors of the hTERT promoter (19, 20) . One such transfection experiment identified pool number 1012, which is the focus of the present studies (Fig. 1A) . Pool number 1012 was subfractionated into 30 subpools of approximately 10 colonies each, and two positive subpools (numbers 17 and 19) were identified (Fig. 1B) . We chose one of them (number 17) for further fractionation steps to yield two pure cDNA clones (numbers 33 and 38; Fig. 1C ). From the sequence analysis, we found that this cDNA encoded the transcription factor E2F-1.
Next, we examined whether E2F-1 represses hTERT promoter activity in other human tumor cell lines, such as 293 cells. We cotransfected the hTERT promoter-firefly luciferase reporter plasmid along with the expression plasmid for E2F-1 into 293 (adenovirus 5 transformed kidney), HeLa (cervical adenocarcinoma), and U2OS (osteosarcoma) cells. Ectopic expression of E2F-1 reduced the hTERT promoter activity in all of these tumor cell lines (Fig. 2 ). In addition, the repressive effect on the hTERT promoter activity was dose dependent, with increasing amounts of transfected E2F-1 consistently reducing reporter expression.
An E2F-1 mutant defective in the transcriptional regulation through the Sp site failed to repress the hTERT promoter in human tumor cells
To understand the mechanism underlying E2F-1-mediated repression of the hTERT promoter in human tumor cells, we examined the domains of E2F-1 required for hTERT promoter repression. To this end, we exploited two E2F-1 mutants that are defective in specific aspects of transcriptional regulation (Fig. 3A) . E2F-1 Y411C is specifically defective in its interaction with pRB (23). E2F-1 ∆1-88 (which lacks N-terminal amino acids 1-88) is intact in its pRBdependent function but is specifically defective in transcriptional regulation through the DNA binding site for Sp (25) . Both mutants retain the domain that binds to E2F consensus binding sites.
To analyze the role of these E2F-1 mutants in hTERT promoter repression, we cotransfected hTERT promoter-firefly luciferase reporter plasmid together with each of the expression plasmids for wild-type and mutant E2F-1 into U2OS cells (Fig. 3B) . Transfection of increasing amounts of the E2F-1 expression plasmid caused repression of the hTERT promoter activity in a dose-dependent manner. Under these conditions, E2F-1 ∆1-88 did not repress hTERT promoter activity, but it activated the hTERT promoter with higher amounts of its expression plasmid. The inability to repress the hTERT promoter by E2F-1 ∆1-88 was also observed with other tumor cells (293 and HeLa; Fig. 3C ). In contrast to E2F-1 ∆1-88, E2F-1 Y411C exhibited repressive activity similar to wild-type E2F-1 in all of these cells (Fig. 3B, C) . Consistent with these results, E2F-1 efficiently repressed the hTERT promoter activity in the Saos-2 (osteosarcoma) cell line, which is functionally pRB deficient (Fig. 3D ). Taken together, these studies raised the possibility that the repressive function of E2F-1 on the hTERT promoter in human tumor cells may involve Sp family protein(s), but not pRB.
Sp sites were important for E2F-1-mediated repression of the hTERT promoter in human tumor cells
We next attempted to identify the hTERT promoter region important for E2F-1-mediated repression. We cotransfected E2F-1 expression plasmid into U2OS cells along with the firefly luciferase reporter plasmids containing the hTERT promoter with serial 5'-deletions from -3396 (Fig. 4A ). Serial deletions from -3396 up to -189 did not affect E2F-1-mediated repression of the hTERT promoter. We then examined the effects of E2F-1 on the 3'-deletion plasmids prepared from the construct p188, which contains the hTERT proximal promoter region from -188 to the immediate upstream part of the translation start codon of the hTERT gene (Fig. 4A) . Serial deletion from the most downstream part of the promoter region of p188 up to -50 did not affect repression of the hTERT promoter by E2F-1. Interestingly, further deletion from -51 to -88 increased the repressive effect mediated by E2F-1, which suggests a possible role of this region in the transcriptional regulation of the hTERT promoter. On the basis of these results, we analyzed the DNA sequences between -188 and -51 which support the repression of the hTERT promoter by E2F-1.
Sequence analysis revealed five potential Sp binding sites in the hTERT promoter region between -188 and -51 (Fig. 4B) . We assessed the effects of E2F-1 on the proximal 188-bp hTERT promoter with these five Sp sites mutated (p188-Sp-m1,2,3,4,5; Fig. 5 ). The expression plasmid of E2F-1 was transfected into 293, HeLa, and U2OS cells along with the firefly luciferase reporter driven by either wild-type or mutant hTERT promoter (Fig. 5) . The hTERT promoter activity in p188 was repressed by two-to fourfold with ectopic expression of E2F-1 in all three tumor cell types. Under these conditions, E2F-1 failed to repress the hTERT promoter activity (e.g., by less than 1.5-fold) when the five Sp sites were mutated (Fig. 5) . This inability to repress the hTERT promoter by E2F-1 was also observed to varying degrees when two or three of these five Sp sites were mutated (J. Won, unpublished observations). These results supported the idea that Sp sites may be involved in the E2F-1-mediated repression of the hTERT promoter in human tumor cells.
Sp1 was strongly associated with the hTERT promoter in human tumor cells
To assess the interaction of Sp family proteins with their putative binding sites in the proximal 188-bp hTERT promoter, we conducted an EMSA. Nuclear extracts were prepared from U2OS cells and were probed with a radiolabeled DNA fragment encompassing Sp site 1 (Fig. 6A) . We found that two DNA-protein complexes were formed (I and II in Fig. 6A ). When these DNAprotein complexes were challenged with anti-Sp1 and anti-Sp3 antibodies, we detected Sp1 in DNA-protein complex I and Sp3 in both DNA-protein complexes (Fig. 6A ). Under these conditions, antibodies against other Sp family members (e.g., Sp2 and Sp4) did not affect these band patterns (J. Won, unpublished observations).
To directly address the interaction of Sp1 and Sp3 with the hTERT promoter in human tumor cells, we used an X-ChIP analysis in U2OS cells (Fig. 6B ). After formaldehyde cross-linking of the U2OS cells, chromatin immunoprecipitation was performed with antibodies directed against Sp1, Sp3, and HA. The precipitated DNA was subjected to PCR with specific primers for the hTERT proximal promoter region. Both Sp1 and Sp3 were associated with the endogenous hTERT promoter in these human tumor cells (Fig. 6B) . Notably, the immunoprecipitates obtained with anti-Sp1 antibody exhibited a much higher association with the hTERT promoter region in comparison with those obtained with anti-Sp3 antibody. Because the affinities of antiSp1 and anti-Sp3 antibodies against the respective antigens seemed not to differ significantly in a series of immunoprecipitation and EMSA experiments (J. Won, unpublished observations), these results may suggest that there is a higher occupancy of hTERT promoter by Sp1 in comparison with Sp3 in U2OS cells. On the basis of these results, we focused on Sp1 as the primarily potential regulatory target of E2F-1 on the hTERT promoter in human tumor cells.
E2F-1 directly inhibited activation of the hTERT promoter by Sp1 in human tumor cells
E2F-1 may repress hTERT promoter activity through down-regulation of endogenous Sp1 expression levels. To address this possibility, we examined endogenous Sp1 protein levels after transfection of increasing amounts of E2F-1 expression plasmid in U2OS cells (Fig. 7A) . Actin was used to normalize the total protein amounts. Protein levels of E2F-1 increased with transfection of its expression plasmid, but Sp1 protein level was not altered under these conditions (Fig. 7A) . Thus, E2F-1-mediated repression of the hTERT promoter through the Sp sites was not due to the down-regulation of endogenous Sp1 protein levels. We also observed no alteration in the protein levels of other Sp family members (Sp2, Sp3, and Sp4) under these conditions (J. Won, unpublished observations). These results suggested that E2F-1 may be directly involved in transcriptional repression of the hTERT promoter through an interaction with Sp1 and/or through masking or impeding the DNA binding of Sp1.
To further investigate the possible interplay of Sp1 and E2F-1 in the regulation of the hTERT promoter, we cotransfected the hTERT promoter-firefly luciferase reporter plasmid into U2OS cells with the expression plasmid for Sp1 in the absence or presence of increasing amounts of the E2F-1 expression plasmid. In the absence of ectopic E2F-1 expression, Sp1 activated the hTERT promoter in a dose-dependent manner (Fig. 7B) . However, this Sp1-mediated activation of the hTERT promoter was sharply inhibited by the coexpression of E2F-1 in a dose-dependent manner (Fig. 7B) . Taken together, these results are consistent with our conclusion that E2F-1 may repress the hTERT promoter activity in tumor cells by suppressing Sp1-mediated transcriptional activation.
E2F-1 activated the hTERT promoter in normal human somatic cells
The activities of the hTERT promoter and telomerase are highly induced in human tumor cells but are highly repressed in most normal somatic cells. Because E2F-1 can repress the hTERT promoter in human tumor cells, we next examined its role in the regulation of the hTERT promoter in normal human somatic cells. We analyzed the effects of ectopic expression of E2F-1 on the hTERT promoter. The expression plasmid for E2F-1 was transfected along with the hTERT promoter-firefly luciferase reporter plasmid into the mortal normal human fibroblast cell lines IMR90, WI38, and HFF. Interestingly, in sharp contrast to the results in human tumor cells, E2F-1 dramatically activated the hTERT promoter in all of these normal human somatic cells (Fig. 8) . This activation was dependent on the increasing amounts of the expression plasmid for E2F-1. Thus, ectopically expressed E2F-1 can act as a repressor of hTERT (in human tumor cells) and as an activator of hTERT (in normal somatic cells).
An E2F-1 mutant defective in the transcriptional regulation through the Sp site can support transactivation of the hTERT promoter in normal human somatic cells
To understand the mechanism underlying E2F-1-mediated activation of the hTERT promoter in normal human somatic cells, we exploited the specific E2F-1 mutants used in our previous analyses (see Fig. 3A) . We cotransfected the hTERT promoter-firefly luciferase reporter plasmid with the expression plasmids for wild-type E2F-1 and E2F-1 mutants (E2F-1 ∆1-88 and E2F-1 Y411C) into IMR90 cells (Fig. 9) . In repeated experiments, E2F-1 Y411C activated the hTERT promoter more than the wild-type E2F-1 did, which indicated that specific abrogation of the interaction with pRB may increase the activation potential of E2F-1. E2F-1 ∆1-88 activated the hTERT promoter in IMR90 cells as well as its wild-type counterpart did. These results suggested that E2F-1 may activate the hTERT promoter in normal human somatic cells through some site(s) other than Sp1 sites.
E2F-1 activated the hTERT promoter through a noncanonical E2F site in normal human somatic cells
The results from the E2F-1 mutant analysis prompted us to search for the region within the hTERT promoter important for the E2F-1-mediated activation of the hTERT promoter in normal human somatic cells. To this end, we cotransfected the E2F-1 expression plasmid along with a series of 5'-and 3'-deletion hTERT promoter-reporter constructs into IMR90 cells (Fig. 10A) . Serial deletion from -3396 up to -189 did not affect the activation of the hTERT promoter by E2F-1. In addition, 3'-serial deletion from the most downstream of the promoter region of p188 up to -50 did not affect the activation of the hTERT promoter by E2F-1. Interestingly, when the region from -51 to -88 in p188 was further deleted, E2F-1 failed to activate the hTERT promoter (Fig. 10A) . These results suggested that the region between -51 and -88 is important in the transcriptional activation of the hTERT promoter by E2F-1.
We examined the location of the potential E2F regulatory site(s) within the region between -51 and -88 of the hTERT promoter (see Fig. 4B ). There was no perfect consensus E2F site within that region of the hTERT promoter. However, the hTERT promoter contains a sequence that perfectly matches a functional E2F binding sequence GCGCGA identified in the cyclin E promoter (26; see E2F-I in Fig. 4B ). This sequence of the hTERT promoter was mutated to GCATGA and was cotransfected along with the E2F-1 expression plasmid into IMR90 cells (Fig.  10B) . The hTERT promoter activity in p188 was activated with ectopic expression of E2F-1. Under these conditions, E2F-1 failed to activate the hTERT promoter with mutation of the E2F site (Fig. 10B) . Furthermore, introduction of the mutation into this E2F site within the construct p1003 also eliminated the activation response of the hTERT promoter to E2F-1 (Fig. 10B) . Thus, this E2F site is critical for activation of the hTERT promoter by E2F-1.
E2F-1, E2F-2, and E2F-3, but not E2F-4 and E2F-5, repressed the hTERT promoter in human tumor cells, whereas all five E2Fs activated the hTERT promoter in normal human somatic cells
E2F-1 belongs to a family of transcription factors composed of six members, which can be divided into three subfamilies---E2F-1, E2F-2, and E2F-3; E2F-4 and E2F-5; and E2F-6-on the basis of structural and functional features. Because most of the cellular genes under transcriptional control by E2F-1 are also susceptible to regulation by other E2F family members, we examined the regulatory functions of E2F-2, E2F-3, E2F-4, and E2F-5 in hTERT promoter activity in normal human somatic cells and tumor cells.
To analyze the effects of the E2F family members on hTERT promoter activity in normal human somatic cells, their expression plasmids were cotransfected along with the hTERT promoterfirefly luciferase reporter plasmid into IMR90, WI38, and HFF cells. All five E2F members activated the hTERT promoter in these human mortal fibroblast cells to different degrees (Fig.  11B) . Under these conditions, c-Myc induced the hTERT promoter by two-to threefold higher than did E2F-1 in IMR90, WI38, and HFF cells (J. Won, unpublished observations). To analyze the effects of the five E2F members in human tumor cells, we tested their transcriptional activities in 293, HeLa, and U2OS cells (Fig. 11A) . E2F-1, E2F-2, and E2F-3 repressed the hTERT promoter activity in all three of these human tumor cell lines. These repressive effects by E2F-1, E2F-2, and E2F-3 were almost comparable to those by Mad1 (J. Won, unpublished observations). However, E2F-4 and E2F-5 did not repress the hTERT promoter activity in these cells; instead, they activated the hTERT promoter activity in the tumor cells to different degrees. The repression and activation of the hTERT promoter mediated by each of these E2F family members were observed to occur in a dose-dependent manner with various amounts of transfected plasmids for corresponding E2F members (J. Won, unpublished observations). Taken together, these results suggested that E2F-1, E2F-2, and E2F-3 in the E2F family specifically exhibit contrasting functions in the hTERT promoter regulation in human normal cells and tumor cells. DISCUSSION E2F-1 has been described as a multifaceted transcription factor: it can mediate both transcriptional activation and repression of target genes, and it can both promote and inhibit cell proliferation and tumorigenesis (27, 28) . However, the molecular mechanism underlying these paradoxical biological activities has not been explained. Interestingly, our studies demonstrated contradictory effects of E2F-1 on the hTERT promoter. Ectopic expression of E2F-1 repressed the hTERT promoter activity in human tumor cells, whereas it activated the hTERT promoter activity in normal human somatic cells. Expression of the hTERT gene and telomerase activity is important for the progression and maintenance of human tumors, and abrogation of the hTERT expression in human tumor cells can induce growth arrest or apoptosis (29, 30) . It is plausible that E2F-1-mediated repression and activation of the hTERT promoter could be related to the tumor-suppressing and oncogenic properties of E2F-1, respectively. Taken together, these results raise an interesting possibility that the paradoxical effects of E2F-1 may at least in part be attributed to its regulation of hTERT promoter activity.
Using E2F-1 mutants defective in specific functions, we obtained an important clue that E2F-1-mediated repression of the hTERT promoter activity may occur through Sp sites within the hTERT promoter (Figs. 3, 4, and 5) . Through a series of experiments, we obtained consistent results supporting the involvement of Sp1 in the transcriptional repression of the hTERT promoter by E2F-1 in human tumor cells (Figs. 6 and 7) . E2F-1 has been reported to interact with Sp1 though the C-terminal region of Sp1 (31) . Interestingly, this region of Sp1 is also crucial for the interactions with other Sp1 proteins to form a homo-multimeric complex, which synergistically activates transcription (32) . In most human tumor cells, hTERT is highly expressed to ensure stable telomeres. To achieve this high level of telomerase activity, synergistic activation of the hTERT promoter through the multimerization of Sp1 could be an important mechanism. Promoters bearing multiple Sp sites have been shown to be activated by Sp1 with a high degree of synergism (32) . The hTERT promoter could be of this type, because five Sp sites are clustered in the hTERT proximal promoter region, the same region that is critical for high levels of transcriptional activation in tumor cells. Therefore, repression of Sp1-mediated activation of the hTERT promoter by E2F-1 in human tumor cells may be due to an inhibition of the formation of the Sp1 multimeric complex on the hTERT promoter.
We found that E2F-2 and E2F-3, in addition to E2F-1, also repressed hTERT promoter activity in human tumor cells (Fig. 11) . However, E2F-4 and E2F-5 failed to repress the hTERT promoter in these tumor cells. It is intriguing that E2F-1, E2F-2, and E2F-3 bind Sp1, whereas E2F-4 and E2F-5 do not (16) . This finding is consistent with our idea that the interaction between E2F and Sp1 is crucial for the repression of the hTERT promoter.
These results for the repression of the hTERT promoter activity are also consistent with previous data showing that ectopic overexpression of E2F-1, E2F-2, and E2F-3 inhibits the transformation process, whereas overexpression of E2F-4 and E2F-5 does not produce this inhibition (33) . Furthermore, E2F-1 ∆1-88, which lacks the ability to repress hTERT promoter activity (Fig. 3B,  C) , also fails to inhibit the transformation process efficiently compared with wild-type E2F-1 (33) . Thus, the down-regulation of hTERT promoter activity may contribute to the inhibitory effects of E2F-1, E2F-2, and E2F-3 on the transformation process.
In contrast to the results in human tumor cells, all five E2F proteins activated the hTERT promoter in normal human somatic cells (Figs. 8 and 11) . Furthermore, analyses of specific E2F-1 mutants in normal human somatic cells indicated that the functional interaction of E2F-1 with Sp1 is dispensable for E2F-1-mediated activation of the hTERT promoter in normal human somatic cells. Using serial deletion and mutational analyses of the hTERT promoter, we found that E2F-1 activates the hTERT promoter through a noncanonical E2F site in normal human somatic cells (Fig. 10) . This E2F site did not match the consensus DNA binding sequence for E2F. However, the sequence of this site was identical to that of the variant E2F site, termed the E2F I site, identified in the cyclin E promoter (26) . Mutation of this one E2F site almost completely abolished the induction of the hTERT promoter by E2F-1 in normal human somatic cells (Fig. 10B) . These results suggest that this site is crucial for the E2F-1-mediated regulation of the hTERT promoter in normal human somatic cells.
During preparation of our manuscript, Crowe et al. reported that E2F-1 represses the hTERT promoter in the human squamous carcinoma cell line SCC25 (34) . This report is in a good agreement with our results for 293, HeLa, U2OS, and Saos-2 tumor cells. In their studies, the major effects for E2F-1-mediated repression of the hTERT promoter were obtained through two other noncanonical E2F sites (see E2F* and E2F** in Fig. 4B ) (34) . However, our results indicate that Sp sites also have a critical role in the transcriptional repression of the hTERT promoter by E2F-1 in several human tumor cell lines tested. We observed almost no effect on the E2F-1-meditated repression when we deleted one of the two previously reported E2F sites (E2F*) (Fig. 4) . Moreover, abrogation of the five Sp sites within the hTERT proximal promoter region significantly decreased the E2F-1-mediated repressive effects (Fig. 5) ; the residual repressive effects of this mutated plasmid can be attributed to the E2F** site reported by Crowe et al. However, this E2F** site seemed to be dispensable in the E2F-1-mediated activation of the hTERT promoter in normal human somatic cells. For example, when the E2F-I site was mutated in p1003, in which the two other E2F sites are still present, activation of the hTERT promoter was almost completely abolished (Fig. 10B) . These results suggest that the E2F site identified in the present studies is the critical DNA element for E2F-1-mediated activation in normal human somatic cells. We cannot discard the possibility that differences in the relative contributions of Sp and E2F sites in hTERT repression in human tumor cells may involve differences in experimental conditions, including different cell lines (SCC25 vs. 293, HeLa, U2OS, and Saos-2) used in the present and previous studies.
On the basis of the regulation of the hTERT promoter by E2F family members, we can propose a plausible regulatory mechanism for the regulation of telomerase activity in highly proliferating tissues. E2F-1, E2F-2, and E2F-3 have been described to be up-regulated in highly proliferating cells (35) (36) (37) (38) (39) . We found that, related to this up-regulation, ectopic overexpression of these three E2Fs repressed the hTERT promoter activity in human tumor cells (with higher proliferation potentials) and activated it in normal cells (with lower proliferation potentials) (Fig. 11A, B) . These demonstrated bifunctional activities of E2Fs upon their up-regulation (or overexpression) lead us to propose the idea that the regulation of E2F family members may help hTERT gene expression to be kept within certain boundaries. In highly proliferating tissues, telomerase activity must be carefully regulated within a certain range to avoid tissue atrophy or tumorigenesis (1, 3, 40) . Taken together, our results suggest that regulation of E2F may function as one of the fine-tuning mechanisms that tightly control hTERT transcription within a certain range in a variety of proliferative conditions. sequences responsible for the E2F-1-mediated repression were in the region between -188 and -89 of the hTERT promoter. One microgram of the E2F-1 expression plasmid was cotransfected into U2OS cells together with 2.5 µg of a series of firefly luciferase reporter plasmids containing the hTERT promoter with serial 5'-or 3'-deletions. A schematic diagram of the firefly luciferase reporter plasmids with serial deletions of the hTERT promoter is presented. The A of the translation start codon (ATG) of the hTERT gene was designated as +1, and the name of each reporter construct was assigned according to the nucleotide number of the 5'-end (5'-deletion constructs) or 5'-end/3'-end (3'-deletion constructs). Luciferase activity was normalized by protein concentration. Results shown are the average of three experiments, and bars indicate standard deviations. B) Sequences of the hTERT proximal promoter and locations of the E-boxes and Sp and E2F sites. The translation start codon ATG is shown in bold, and A of the start codon is designated as +1. The position of -188 is also shown. The sequences that were mutated are indicated by asterisks, with the substituted bases as just presented. The E2F sites designated as E2F* and E2F** were described previously (34) . A) The DNA sequences mediating the transactivation of the hTERT promoter by E2F-1 were in the region between -88 and -51 of the hTERT promoter. E2F-1 expression plasmid (3 µg) was cotransfected into IMR90 cells together with 4 µg of a series of firefly luciferase reporter plasmids containing hTERT promoter with serial 5'-or 3'-deletions. Luciferase activity was normalized by protein concentration. Results shown are the average of three experiments, and bars indicate standard deviations. B) A noncanonical E2F site within the region between -88 and -51 of the hTERT promoter was responsible for the transactivation of the hTERT promoter by ectopically expressed E2F-1. E2F-1 expression plasmid (3 µg) was cotransfected into IMR90 cells together with 4 µg of the firefly luciferase reporter plasmid containing either wild-type (p1003 and p188) or site mutant (p1003-E2F-m and p188-E2F-m) hTERT promoter. The sequence of the noncanonical E2F site (E2F-I site) GCGCGA was mutated to GCATGA. 
